Home > Publications Database > 5-methylcytosine and 5-hydroxymethylcytosine in brains of patients with multiple system atrophy and patients with Parkinson's disease. > print |
001 | 140551 | ||
005 | 20240722132627.0 | ||
024 | 7 | _ | |a 10.1016/j.jchemneu.2018.12.005 |2 doi |
024 | 7 | _ | |a pmid:30557654 |2 pmid |
024 | 7 | _ | |a 0891-0618 |2 ISSN |
024 | 7 | _ | |a 1873-6300 |2 ISSN |
024 | 7 | _ | |a altmetric:52811860 |2 altmetric |
037 | _ | _ | |a DZNE-2020-06873 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Kaut, Oliver |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
245 | _ | _ | |a 5-methylcytosine and 5-hydroxymethylcytosine in brains of patients with multiple system atrophy and patients with Parkinson's disease. |
260 | _ | _ | |a Amsterdam [u.a.] |c 2019 |b Elsevier Science |
264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2019-03-01 |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1721647557_12030 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder of unknown etiology, characterized pathologically by α-synuclein aggregates preferentially found in oligodendroglial cells. DNA methylation has emerged as a mechanism of regulation of α-synuclein expression. Reduced 5-methylcytosine (5-mC) DNA methylation of α-synuclein has been found in the brains of patients with Parkinson's disease (PD). 5-hydroxymethylcytosine (5-hmC) methylation is another epigenetic modification of DNA. It is involved in the de-methylation of DNA, gene regulation, and DNA repair mechanisms. Here, we examined sections of human paraffin-embedded brain tissue from the cerebellum and brain stem, including the substantia nigra pars compacta, of patients with PD (n = 8) and MSA (n = 8) as well as age-matched controls (n = 8). The neocortical tissue of PD patients (n = 10) and controls (n = 10) was also examined. Using immunohistochemistry, we analyzed the expression of 5-mC and 5-hmC with an automatic, rater-independent semi-quantification method. We found a significant upregulation of 5-mC, but not 5-hmC, in cortical sections from PD patients. The brain stem and substantia nigra, and in particular the dopaminergic neurons, showed unchanged levels of both 5-mC- and 5-hmC-immunoreactivity in all groups. In the cerebellum, 5-mC was significantly decreased only in MSA patients in the granule cell layer; in contrast, 5-hmC was significantly upregulated in the cerebellar white matter of both PD and MSA patients. Our study showed different levels of expression of total 5-mC and 5-hmC methylation across different brain regions in PD and for the first time in MSA. Our results indicate that 5-mC may be relevant in MSA. The underlying mechanism of the differential 5-mC and 5-hmC expression remains unclear. |
536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
542 | _ | _ | |i 2019-03-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
650 | _ | 2 | |a 5-Methylcytosine: analogs & derivatives |2 MeSH |
650 | _ | 2 | |a 5-Methylcytosine: analysis |2 MeSH |
650 | _ | 2 | |a 5-Methylcytosine: metabolism |2 MeSH |
650 | _ | 2 | |a Aged |2 MeSH |
650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
650 | _ | 2 | |a Brain: metabolism |2 MeSH |
650 | _ | 2 | |a Female |2 MeSH |
650 | _ | 2 | |a Humans |2 MeSH |
650 | _ | 2 | |a Male |2 MeSH |
650 | _ | 2 | |a Middle Aged |2 MeSH |
650 | _ | 2 | |a Multiple System Atrophy: metabolism |2 MeSH |
650 | _ | 2 | |a Parkinson Disease: metabolism |2 MeSH |
693 | _ | _ | |0 EXP:(DE-2719)IDAF-20190308 |5 EXP:(DE-2719)IDAF-20190308 |e Image and Data Analysis Facility (CRFS-IDAF) / Bonn |x 0 |
700 | 1 | _ | |a Kuchelmeister, Klaus |b 1 |
700 | 1 | _ | |a Möhl, Christoph |0 P:(DE-2719)2810422 |b 2 |u dzne |
700 | 1 | _ | |a Wüllner, Ullrich |0 P:(DE-2719)2000056 |b 3 |e Last author |u dzne |
773 | 1 | 8 | |a 10.1016/j.jchemneu.2018.12.005 |b : Elsevier BV, 2019-03-01 |p 41-48 |3 journal-article |2 Crossref |t Journal of Chemical Neuroanatomy |v 96 |y 2019 |x 0891-0618 |
773 | _ | _ | |a 10.1016/j.jchemneu.2018.12.005 |g Vol. 96, p. 41 - 48 |0 PERI:(DE-600)2006655-7 |q 96<41 - 48 |p 41-48 |t Journal of chemical neuroanatomy |v 96 |y 2019 |x 0891-0618 |
856 | 4 | _ | |u https://pub.dzne.de/record/140551/files/DZNE-2020-06873_Restricted.pdf |
856 | 4 | _ | |u https://pub.dzne.de/record/140551/files/DZNE-2020-06873_Restricted.pdf?subformat=pdfa |x pdfa |
909 | C | O | |p VDB |o oai:pub.dzne.de:140551 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2810422 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2000056 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
914 | 1 | _ | |y 2019 |
915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-11 |w ger |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-11 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-11 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-11 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-11 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-11 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2022-11-11 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J CHEM NEUROANAT : 2021 |d 2022-11-11 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-11 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-11 |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-11 |
915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-11 |
920 | 1 | _ | |0 I:(DE-2719)1011302 |k AG Wüllner |l Biomarker Parkinson's Disease |x 0 |
920 | 1 | _ | |0 I:(DE-2719)1040200 |k IDAF |l Image and Data Analysis (CRFS-IDAF) |x 1 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-2719)1011302 |
980 | _ | _ | |a I:(DE-2719)1040200 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|